Development of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)

Diabetes Obesity Metabolism

Stewart

et al. 2019

Self Cite

Aim When selecting treatments for type 2 diabetes (T2D), it is important to consider not only efficacy and safety, but also other treatment attributes that have an impact on patient preference. The objective of this study was to examine preference between injection devices used for two weekly GLP‐1 receptor agonists. Materials and Methods The PREFER study was an open‐label, multicentre, randomized, crossover study assessing patient preference for dulaglutide and semaglutide injection devices among injection‐naïve patients receiving oral medication for type 2 diabetes. After being trained to use each device, participants performed all steps of injection preparation and administered mock injections into an injection pad. Time‐to‐train (TTT) for each device was assessed in a subset. Results There were 310 evaluable participants (48.4% female; mean age, 60.0 years; 78 participants in the TTT subgroup). More participants preferred the dulaglutide device than the semaglutide device (84.2% vs. 12.3%; P < 0.0001). More participants perceived the dulaglutide device to have greater ease of use (86.8% vs. 6.8%; P < 0.0001). After preparing and using the devices, more participants were willing to use the dulaglutide device (93.5%) than the semaglutide device (45.8%). Training participants to use the dulaglutide device required less time than the semaglutide device (3.38 vs. 8.14 minutes; P < 0.0001). Conclusions Participants with type 2 diabetes preferred the dulaglutide injection device to the semaglutide injection device. If patients prefer a device, they may be more willing to use the medication, which could result in better health outcomes. Furthermore, a shorter training time for injection devices may be helpful in busy clinical practice settings.

Section: Methodsmentioning

confidence: 99%

Section: Diabetes Injection Device Preference Questionnairementioning

confidence: 99%

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)

Diabetes Obesity Metabolism

Stewart

et al. 2019

Self Cite

“…The subset of patients who had experience with both dulaglutide and liraglutide also completed the DID-PQ. The DID instruments were developed based on qualitative research with patients treated with non-insulin injectable medication 34,35 . The questionnaires also demonstrated reliability and validity in a psychometric study among patients using a wide range of non-insulin injection devices 36,37 .…”

Section: Methodsmentioning

confidence: 99%

Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes

Current Medical Research and Opinion

Currie

et al. 2018

Self Cite

“…The DID-PQ was designed to assess patient preferences between two non-insulin injection devices [ 6 , 7 ]. The 10 questionnaire items were developed based on qualitative research with patients.…”

Section: Methodsmentioning

confidence: 99%

“…Therefore, two patient-reported outcome (PRO) measures have been developed to assess patient perceptions of injection devices used to administer these non-insulin injectable medications: the Diabetes Injection Device Experience Questionnaire (DID-EQ) and the Diabetes Injection Device Preference Questionnaire (DID-PQ) [ 6 ]. The DID-EQ was designed to assess perceptions of a single injection device, and it has demonstrated reliability and validity in patients treated with GLP-1 RAs [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Validity and analysis of the Diabetes Injection Device Preference Questionnaire (DID-PQ)

Currie

et al. 2020

J Patient Rep Outcomes

Self Cite

Introduction The Diabetes Injection Device Preference Questionnaire (DID-PQ) was designed to assess patient preference between two non-insulin injection devices. In a recent crossover study, people with type 2 diabetes (T2D) completed the DID-PQ after performing mock injections with two non-insulin injection devices. The purpose of the current analysis was to use these data to assess construct validity of the DID-PQ and demonstrate one way to test whether there is a significant preference for one injection device over another. Methods Data were from an open-label, multicenter, randomized, crossover study assessing preference between the dulaglutide and semaglutide injection pens. In addition to the 10-item DID-PQ, people with T2D completed a global item assessing overall preference. DID-PQ responses were compared to the global preference item (percent agreement, Gwet’s AC1, prevalence-adjusted and bias-adjusted Kappa [PABAK]). For each item of the DID-PQ, a two-sided binomial test assessed whether the difference in preference was statistically significant. Results The sample included 310 participants (48.4% female; mean age = 60.0). The DID-PQ had minimal missing data. There was strong concordance (percent agreement > 78%) between the global preference item and all DID-PQ items except item 6, which assesses preference related to needle size (59.7%). The Gwet AC1 and PABAK statistics also indicated strong agreement between the global preference item and all DID-PQ items except item 6. There was a statistically significant difference (p < 0.0001) in preference on every DID-PQ item, with more participants preferring the dulaglutide device. Discussion Patient preference has been recommended as a “major factor driving the choice of medication” in a consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Current findings suggest that the DID-PQ may be a useful tool for providing insight into preferences of people with T2D using non-insulin injectable medication.